Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
about
Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerThe Evolution of Therapies in Non-Small Cell Lung CancerOvercoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationThe latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanomaNeoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancerManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerSecond-Line Therapy for Advanced NSCLCAnalysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceGefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationUnderstanding, recognizing, and managing toxicities of targeted anticancer therapies.Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancerThe quest to overcome resistance to EGFR-targeted therapies in cancer.A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumorsNew developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyThe level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsmDrug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceDual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsGefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control StudyFool's gold, lost treasures, and the randomized clinical trial.Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung CancerPeroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.Fibroblasts contribute to melanoma tumor growth and drug resistance.Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer.Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma.Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with (18)F-3'deoxy-3'fluoro-L-thymidine positron emission tomography/computed tomographyTyrosine kinase inhibitors in lung cancer.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASSubsequent treatment of epidermal growth factor receptor-tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinomaAdvances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib.Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
P2860
Q26745427-2093C54A-D8CA-4950-845A-405F999AA52CQ26786932-0F972787-A292-4F51-BAF1-00E530D19A51Q26795556-F7359AB1-25EB-40EA-A62F-10DA77534AF6Q26823305-838D9FA1-730C-4E60-A93A-E5384F2E03EFQ26824310-CC27250D-E1E5-4A99-84C9-9B6A367C1187Q26863742-8289D997-A3E7-4EEE-9D19-7FD494841AEDQ26865779-6E1D93EB-1F01-4860-BED1-C201E768E5D2Q27002398-C8509511-2446-4344-AEBE-2D189F080E59Q27852116-E3A6B09E-BD13-4979-87AE-B7FE775223C4Q27852806-B621F86A-98D9-4D2E-9518-6B6E1BD191ADQ28075291-DD143685-565E-4AA0-B5EA-D22C5F43212AQ28083239-2F5D0312-C358-4051-88AF-7271475515B3Q28534577-D7C21F39-E4BF-4B96-B758-6BC56C726EEEQ33408049-BFFA5A6A-439E-4B9C-B737-7C6F0E69438DQ33710152-7E05FE11-5731-4585-B071-EC0899FE9401Q33725976-7038CAC0-202E-43BD-8F47-613AAB9C963FQ33732128-01AF6064-2394-4E81-9020-3E562831B966Q33824552-C97E6660-B28D-4C0D-AE87-2C80FA197738Q33857865-04694A3F-F407-4FD0-A4A2-92FA6D54A5B1Q33938441-50D0BEA6-48C4-4B84-A52F-ADE26C75F1D6Q33948614-3FA09F85-6557-47EC-BA2A-F89D638C8381Q34011705-76A3F607-7960-44E7-BC37-33BF48DC8295Q34135471-1868039A-F1EF-483B-8512-C5B2A3DDF90CQ34369323-0F0B8403-D353-473A-BA9B-30C3AF7B4232Q34669260-A8C0758C-6025-42B1-A4A3-1DBA87A0FF11Q34865629-3CF28369-CA18-4DD7-BB80-AEE875FCB870Q35051779-8F2D580C-F307-489C-BC02-60BB9726C483Q35136424-EC651C64-1A90-4B48-B99D-D591AE7909AEQ35196345-7FDD016F-3DCD-4FBD-BD24-73011E620DF2Q35607701-5E92C62C-5FDD-4328-8570-CB9F3834EB65Q35631635-EEED93F1-6990-459E-9166-FFC5AA99FE07Q35663566-74783A9C-C5EE-4082-885C-25671640DB13Q35681695-91A8BFA8-E8A8-447D-B079-46FCEAE62EA8Q35842799-FEBABDC7-D2C6-4E7C-86C1-F15D6B3B762BQ35908430-76A790AA-741C-4FF8-B72F-56E3365869D1Q36040606-D2A8580A-BD6C-46EE-888F-4052039F2AECQ36247850-0E96F2C0-6FB8-442E-8BD7-FF8F09A2FDCFQ36358523-5CC90025-9E65-4A86-B76A-64C37FEBD037Q36382921-8ECD648B-A258-4045-8994-78B67EA0C800Q36413062-9A89328A-0AFB-40A9-A2FD-64FADF560C3B
P2860
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Disease flare after tyrosine k ...... ons for clinical trial design.
@en
Disease flare after tyrosine k ...... ons for clinical trial design.
@nl
type
label
Disease flare after tyrosine k ...... ons for clinical trial design.
@en
Disease flare after tyrosine k ...... ons for clinical trial design.
@nl
prefLabel
Disease flare after tyrosine k ...... ons for clinical trial design.
@en
Disease flare after tyrosine k ...... ons for clinical trial design.
@nl
P2093
P2860
P1476
Disease flare after tyrosine k ...... ions for clinical trial design
@en
P2093
Camelia S Sima
Geoffrey R Oxnard
Gregory J Riely
Vincent A Miller
P2860
P304
P356
10.1158/1078-0432.CCR-11-1468
P407
P577
2011-08-19T00:00:00Z